ArticleNeuroImmune pharmacology and therapeutics2025
Co-exposure of antiretroviral therapy and nicotine induces brain metabolic impairments in a mouse model.
Article in NeuroImmune pharmacology and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Objectives: Anti-retroviral therapy (ART) drastically improves human immunodeficiency virus type 1 (HIV-1) outcomes, but may induce adverse neurochemical changes. Interactive effects of ART with recreational drugs are unknown. Notably, people living with HIV-1 (PLWH) smoke at twice the rate of the general population and are more prone to tobacco-linked illness. Thus, chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI) was employed to investigate potential ART-nicotine co-morbid neuro-metabolomic influence. Methods: 16 healthy, male, C57BL/6 mice were divided into four groups: vehicle-treatment, ART-treatment, nicotine-treatment, and ART-nicotine co-treatment. CEST-MRI was performed at day 12 following daily treatments to determine effects on neurometabolic profiles. Magnetic resonance spectroscopy (MRS) was used to contextualize metabolic outcomes. Results: CEST-MRI detected significantly lower 3 ppm contrast in ART, nicotine, and co-treatment groups, suggesting ART- and nicotine-linked glutamate alteration. Co-treatment induced significantly higher hippocampal nuclear Overhauser effects (NOE) compared to ART-treatment, whereas individual treatments lacked effect on NOE, indicating adverse effect on membrane lipids. MRS confirmed CEST findings of membrane turnover, detecting significantly lower hippocampal total choline across all groups compared to controls. Conclusions: CEST-MRI detects adverse neuro-metabolomic alterations induced by ART- and nicotine-exposure. This warrants investigation with HIV-1-infection to assess potential influences of co-exposure on PLWH cognition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.